[1]Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol, 2005, 6(6):383-392.
[2] Rapp SR, Feldman SR, Exum L, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol , 1999;41(3 pt 1):401-407.
[3] Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005, 53(1 suppl 1):S17-S25.
[4] Charakida A, Dadzie O, Teixeria F, et al. Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. Expert Opin Pharmacol, 2006, 7(5):597-606.
[5] SimonsenL, Hoy G, Didriksen E, Persson J, et al. Development of a new formulation combining calcipotriol and betamethasone in an ointment vehicle. Drug Dev Indust Pharm, 2004, 30(10):1095-1102.
[6] Saraceno R, Andreassi L, Ayala F,Efficacy, et al. Safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat, 2007, 18(6):361-365.
[7] Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag, 2008, 4(1):141-148.
[8] Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol, 2006, 45(8):970-975.
[9] Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.. Brit J Dermatol, 2006, 154(6):1155-1160.
[10] Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of two-compound product containing calcipotriol/betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venerol, 2006, 20(1):39-44. |